The emerging role of cannabinoid neuromodulators in symptom management

Mellar Davis, Vincent Maida, Paul Daeninck, Joseph Pergolizzi

Research output: Contribution to journalArticlepeer-review


Introduction: The cannabinoids nabilone (Cesamet) and dronabinol (Marinol) are indicated for the management of chemotherapy-induced nausea and vomiting (CINV) in cancer patients who have failed to respond adequately to conventional antiemetic therapy. Discussion: The endocannabinoid (CB) system interacts with numerous other systems and pharmaceutical cannabinoids target ubiquitous CB1 and CB2 receptors in the central nervous system and periphery, relieving nausea and vomiting and pain. Summary: The benefits of this novel class of medications in cancer may extend beyond CINV, as indicated by data from preclinical studies and animal models.

Original languageEnglish (US)
Pages (from-to)63-71
Number of pages9
JournalSupportive Care in Cancer
Issue number1
StatePublished - Jan 2007


  • Cannabinoids
  • CB1 and CB2 receptors
  • Chemotherapy-induced nausea and vomiting
  • Pain

ASJC Scopus subject areas

  • Oncology
  • Nursing(all)


Dive into the research topics of 'The emerging role of cannabinoid neuromodulators in symptom management'. Together they form a unique fingerprint.

Cite this